S
SRPT
Sarepta Therapeutics Inc
23.23
+1.10+4.97%After Hours: 22.95 -0.28 -1.21%19:56 04/02 EDT
OPEN/PREV CLOSE21.93/22.13
TODAY RANGE21.62-23.29
VOL3.16M
MARKET CAP2.44B
52 WEEK RANGE10.42-67.47
AVG VOL (3M)3.03M
% TURNOVER3.01%
TURNOVER--
P/E (TTM)-3.2601
% RANGE7.57%
EPS(TTM)-7.1255
P/E(FORWARD)7.93
P/B2.138
BVPS10.87
DIVIDEND--
P/S1.109
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.31B
SHARES OUTSTANDING104.99M
NEXT EARNINGS05/04-05/08
FREE FLOAT99.57M
LOT SIZE1
EX-DATE07/12/2012
News
Press Releases
Financial Reports
Profile
Simply Wall St·11h ago
Sarepta Therapeutics (SRPT) Is Up 16.3% After Early siRNA Muscle Data Validates Avß6 Platform
TipRanks·3d ago
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
Seeking Alpha·5d ago
Tango Therapeutics is the best performing healthcare stock in March
Simply Wall St·5d ago
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Swings
Benzinga·03/27 17:09
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?
NASDAQ·03/27 15:30
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
Simply Wall St·03/27 07:07
Could Sarepta Therapeutics’ (SRPT) New siRNA Data Mark a Turning Point Beyond Duchenne Therapies?
Seeking Alpha·03/26 20:27
Wave Life Sciences: WVE-007 Data Leaves Biotech Shaken And Stirred (Downgrade)
NASDAQ·03/26 17:14
SRPT Stock Surges on Promising Early Results From siRNA Programs
Seeking Alpha·03/26 16:41
Sarepta Therapeutics: It's Too Early To Get Excited About siRNA Data
Dow Jones·03/26 15:35
Sarepta Therapeutics Is Maintained at Sell by Citigroup
Dow Jones·03/26 15:35
Sarepta Therapeutics Price Target Raised to $13.00/Share From $9.00 by Citigroup
Benzinga·03/26 15:25
Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.